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Post-translational prenylation of heterotrimeric G
protein g subunits is essential for high affinity a-bg and
a-bg-receptor interactions, suggesting that the prenyl
group is an important domain in the bg dimer. To deter-
mine the role of the prenyl modification in the interac-
tion of bg dimers with effectors, the CAAX (where A
indicates alipathic amino acid) motifs in the g1, g2, and
g11 subunits were altered to direct modification with
different prenyl groups. Six recombinant bg dimers
were overexpressed in baculovirus-infected Sf9 insect
cells, purified, and examined for their ability to stimu-
late three phospholipase C-b isozymes and type II ad-
enylyl cyclase. The native b1g2 dimer (g subunit modi-
fied with geranylgeranyl) is more potent and effective in
activating phospholipase C-b than either the b1g1 (far-
nesyl) or the b1g11 (farnesyl) dimers. However, farnesyl
modification of the g subunit in the b1g2 dimer (b1g2-
L71S) caused a decrement in its ability to activate phos-
pholipase C-b. In contrast, both the b1g1-S74L (gera-
nylgeranyl) and the b1g11-S73L (geranylgeranyl) dimers
were more active than the native forms. The b1g2 dimer
activates type II adenylyl cyclase about 12-fold; how-
ever, neither the b1g1 nor the b1g11 dimers activate the
enzyme. As was the case with phospholipase C-b, the
b1g2-L71S dimer was less able to activate adenylyl cyclase
than the native b1g2 dimer. Interestingly, neither the
b1g1-S74L nor the b1g11-S73L dimers stimulated adenylyl
cyclase. The results suggest that both the amino acid
sequence of the g subunit and its prenyl group play a
role in determining the activity of the bg-effector
complex.
Heterotrimeric G proteins1 are transducers of numerous ex-
tracellular signals from seven transmembrane receptors to in-
tracellular effectors (1–4). G proteins are composed of a, b, and
g subunits and associate with the inner side of the plasma
membrane. Receptor activation catalyzes the exchange of GDP
for GTP on the a subunit, resulting in dissociation of the
GTP-liganded a subunit from the bg dimer (1). Both the GTP-
bound form of the a subunit and the released bg dimer regulate
a variety of effectors, including PLC-b (5, 6) and adenylyl
cyclases (7, 8). To date, 7 b subunits and 11 g subunits have
been identified in mammalian systems (9–15). Selective as-
sembly of bg heterodimers from these proteins may produce a
large number of unique complexes that differ in their interac-
tions with a subunits, receptors, and effectors. While the first
four b subunits identified, b1–b4, are 85–90% identical in pri-
mary amino acid sequence (9), the g subunits are much more
divergent. For example, the g1 and g5 subunits are only 25%
identical. Thus, the g subunits may impart some specificity to
the bg signal.
The G protein g subunits are subject to post-translational
modification by the addition of isoprenoid lipids to an invariant
cysteine residue in the CAAX motif at their C terminus (15–17).
The last amino acid (X) of the CAAX motif is an important
determinant for modification by one of two distinct isoprenoids,
the 15-carbon farnesyl group or the 20-carbon geranylgeranyl
group. Among the 11 known g subunits, the g1, g8, and g11
subunits are thought to be modified with the addition of a
15-carbon farnesyl group, whereas the other g subunits contain
a 20-carbon geranylgeranyl group (10). The g11 subunit was
recently identified as a widely expressed g subunit that is 76%
identical to the g1 subunit (10, 18). However, the function of bg
dimers containing the g11 subunit has not been studied. More-
over, the significance of farnesyl versus geranylgeranyl modi-
fication of the g subunit in bg subunit-mediated activation of
effectors has not been established.
Lipid modification is important for anchoring the bg subunit
to the membrane (17, 19, 20), but the prenyl group may also
play a major role in determining functional interaction with
other proteins (15, 17, 21). For instance, prenylation of the g
subunit is necessary for formation of an active transducin a-bg
complex (22, 23), for translocation of the b-adrenergic receptor
kinase to the plasma membrane (24), for high affinity interac-
tions with either a subunits or adenylyl cyclases (25), and for
stimulation of PLC-b by the b1g1 dimer (26). Since the g sub-
units may have different primary amino acid sequences and
different prenyl groups at their C terminus, investigators have
attempted to determine whether the type of prenyl group is an
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important determinant of the activity of the bg dimer. Some
studies suggest that bg dimers containing the farnesylated g1
subunit couple rhodopsin to the Gt a subunit more effectively
(27, 28), while others show a small increase in the activity of bg
dimers containing a geranylgeranylated g1 subunit in receptor-
coupling assays (29). We have determined that bg dimers con-
taining a geranylgeranyl group on the g subunit couple the Gi
a subunit to the A1 adenosine receptor more effectively than
those containing a farnesyl group (30). Overall, these results
suggest that the type of prenyl group on the g subunit does play
an important role in determining the activity of bg dimers.
Most investigators have considered that the prenyl group is
involved in tethering the bg subunit to the membrane (17, 19,
20). However, the recent x-ray crystal structure of a phosdu-
cin-bg complex, which was crystallized with an intact g subunit
containing a farnesyl group, shows that the isoprenoid group
folds into a hydrophobic pocket formed by blades 6 and 7 of the
b propeller (31). Interestingly, the conformation of the b sub-
unit in this complex is different from the conformation of the
free bg dimer (32). Thus, it is possible that there is an active
conformation of the bg dimer, which occurs upon binding to
effectors, and that the prenyl group participates in establishing
this conformation. These observations provide a compelling
reason to examine the ability of bg dimers in which the g
subunit contains different isoprenoid lipids in regulating
effectors.
We have reported previously that the prenyl group on the g1
and g2 subunits can be altered by mutation of the last amino
acid (X) in the CAAX motif at their C terminus (30, 33). Ex-
pression of the mutant g subunits in Sf9 cells with a b subunit
allows formation of functional bg dimers in which the lipid on
the g subunit has been changed from farnesyl to geranylgera-
nyl or vice versa (30, 33). Using this approach, we have purified
six recombinant bg dimers containing g subunits with native or
altered prenyl groups and verified that the altered CAAX se-
quences result in the expected post-translational modifications
using mass spectrometry. We examined the effects of the b1g2,
b1g1, and b1g11 dimers and their prenyl mutants on the activity
of PLC-b and type II adenylyl cyclase. The results indicate that
both the primary amino acid sequence of the g subunits and the
type of prenyl group on the g subunit are important determi-
nants of the activation of PLC-b and type II adenylyl cyclase.
EXPERIMENTAL PROCEDURES
Construction of Recombinant Baculoviruses—The recombinant bacu-
loviruses encoding the aS, b1, g1, g2 subunits (34, 35), and the g1 and g2
subunits with altered prenylation sequences in the CAAX motifs, g1-S74L
and g2-L71S, were prepared as described (33). A full-length cDNA encod-
ing the human g11 protein was identified in the expressed sequence tag
data base and obtained from Research Genetics, Inc. (g11, GenBank
TM
accession number H00850). To minimize the length of the construct 59
from the ATG start codon, the polymerase chain reaction was used to
add a SmaI restriction site to the 59 end of g11. For the g11 cDNA, the
primers used were: sense primer, 59-TCCCGGGCGAAAATGCCTGCC-
39; antisense primer, 59-CCACTTAGGATGCAGTTTCTCCC-39. The po-
lymerase chain reaction products were subcloned into the pCNTR shut-
tle vector, and the g11 coding sequence excised from pCNTR with SmaI
and XbaI was ligated into these sites in the baculovirus transfer vector,
pVL1393. The cDNA encoding a g11 with the altered prenylation se-
quence in the CAAX motif, g11-S73L, was constructed with the same
strategy. Modification of the C-terminal CAAX motif of g11 was per-
formed using polymerase chain reaction to introduce a CVIS 3 CVIL
into the CAAX sequence. To produce the g11-S73L cDNA, the primers
used were: sense primer, 59-TCCCGGGCGAAAATGCCTGCC-39; anti-
sense primer, 59-TTTATAAAATAACACAGCTGCC-39. The polymerase
chain reaction products were subcloned into the pCNTR shuttle vector,
digested with SmaI and XbaI, and ligated into these sites in the
pVL1393 transfer vector. The completed constructs of both g11 and
g11-S73L in the pVL1393 transfer vector were sequenced to confirm the
fidelity of the g sequences. Recombinant baculoviruses were produced
by co-transfecting each recombinant plasmid DNA with linear wild type
BaculoGold® viral DNA (PharMingen) into Sf9 cells as described (36).
The recombinant baculoviruses were purified by one round of plaque
purification (37).
Expression and Purification of Recombinant G Protein bg Sub-
units—G protein a and bg subunits were overexpressed by infecting Sf9
insect cells with recombinant baculoviruses as described (34, 35). Sf9
cells were co-infected at a multiplicity of infection of 3 with the appro-
priate b and g recombinant baculoviruses and harvested 48 h after
infection. The bg subunits were extracted from frozen cell pellets with
0.1% Genapol C-100 and purified on a DEAE column followed by affin-
ity chromatography on a Gi1-a-agarose column as described (35). The Gs
a subunit used in the adenylyl cyclase assays was prepared from a 0.1%
(w/v) CHAPS extract of crude cell lysates as described (36).
Purification of Phospholipase C-b—Recombinant turkey PLC-b and
human PLC-b1 and PLC-b2 were purified to homogeneity following
overexpression in baculovirus-infected Sf9 insect cells using chroma-
tography on Q-Sepharose FF, heparin-Sepharose CL-6B, HPHT hy-
droxylapatite, Sephacryl S-300, and FPLC Mono Q HR 5/5 columns as
described previously (38, 39).
Analysis of the Post-translational Processing of g Subunits by Mass
Spectrometry—Full processing of the g subunit requires the addition of
either a farnesyl or a geranylgeranyl group to the C-terminal cysteine in
the CAAX motif, the removal of the three C-terminal amino acids
(AAX), and the addition of a carboxymethyl group to the C terminus (16,
33). To determine the extent of the post-translational lipid modification
of the g subunits, the six purified bg dimers used in this study were
analyzed by electrospray ionization mass spectrometry as described
previously (33). The result of this analysis showed that 96% of the
native g1 subunit contained the expected farnesyl group and had a
completely processed C terminus. Similarly, 87% of the prenyl mutant,
g1-S74L, contained the geranylgeranyl group and was fully processed at
its C terminus. Ninety-one percent of the g2 subunit and 70% of the g11
subunit were found to have the expected geranylgeranyl and farnesyl
groups, respectively, and a completely processed C terminus. The pre-
nyl mutants of these two g subunits, g2-L71S and g11-S73L, were fully
processed with expected isoprenoid lipids to the extent of 95 and 87%,
respectively. Therefore, all g subunits used in this study contain the
expected isoprenoid lipid at the C terminus and are capable of high-
affinity interactions with a subunits, receptors and effectors.
Preparation of Large Unilamellar Vesicles—Phospholipid vesicles
were prepared as described (40). Briefly, phospholipids were mixed at a
molar ratio of 4:1 of phosphatidylethanolamine to PIP2 with [inositol-
2-3H]PIP2 in a buffer containing 50 mM HEPES, pH 8.0, 3 mM EGTA, 80
mM KCl, 1 mM dithiothreitol and the mixture dried under argon. The
dried lipid was suspended with 3.0 ml of the above buffer to give final
concentrations of 1 mM phosphatidylethanolamine, 250 mM PIP2, and
800 cpm/ml [3H]PIP2 and hydrated in the dark at room temperature.
Extruded large unilamellar vesicles were formed from multilamellar
vesicles by vortexing the lipid solution followed by 10 extrusion cycles
through a stack of two polycarbonate filters using a mini-extruder
(Avanti Polar Lipids, Inc.) (41). After extrusion, the final lipid concen-
tration (phosphatidylethanolamine and PIP2) was about 1100 mM. Ex-
truded large unilamellar vesicles were stored under argon at 4 °C until
use.
Reconstitution of bg Dimers to Large Unilamellar Vesicles by Gel
Filtration—CHAPS-solubilized bg subunits (ranging from 10 ng to 10
mg) were mixed with vesicles in a volume of 200 ml. The final CHAPS
concentration in the mixture was held to 0.01%. After reconstituting the
mixture on ice for 30 min, the vesicles were applied to a 2-ml gel
filtration column prepared with Ultrogel AcA34 as described previously
(40, 42). The column was pre-equilibrated at 4 °C with buffer containing
20 mM HEPES, pH 8.0, 2 mM MgCl2, 100 mM NaCl, and 1 mM EDTA
(450 ml/min). The vesicles reconstituted with bg dimers were eluted at
the void volume of the column in a total volume of about 900 ml. This
protocol has been demonstrated to remove more than 98% of the deter-
gent from the vesicles (42, 43) and to resolve the vesicles from the free
bg dimers (40). The concentration of lipid in each fraction was moni-
tored by counting the incorporated [3H]PIP2, and the amount of bg
protein inserted into the vesicles was quantified by silver staining as
described below. The second fraction from the AcA34 column contained
vesicles with the least amount of free bg dimer and were used in all
experiments (40).
Measurement of Phospholipase C-b Activity—Reaction buffer con-
taining 50 mM HEPES, pH 8.0, 17 mM NaCl, 67 mM KCl, 0.83 mM
MgCl2, 0.17 mM EDTA, 3 mM EGTA, 1 mM dithiothreitol, and 1 mg/ml
BSA was added to 70 ml of gel-filtered vesicles (fraction 2) in a total
volume of 80 ml. Controls were performed using column-reconstituted
vesicles without bg dimers. The reactions were initiated by adding 10
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ng of PLC-b and 3 mM free Ca21 and placing the mixture in a 30 °C
water bath. After a 15-min incubation, the reactions were terminated
by transferring each assay tube to a 4 °C ice bath and adding 200 ml of
ice-cold 10% trichloroacetic acid followed by the addition of 100 ml of 10
mg/ml BSA (40). The assay mixtures were centrifuged to remove pre-
cipitated protein and intact PIP2 and the [
3H]inositol 1,4,5-trisphos-
phate released into the supernatant quantitated by liquid scintillation
spectrometry (44, 45).
Measurement of Adenylyl Cyclase Activity—Adenylyl cyclase activity
was measured as described previously (36, 46). Briefly, Sf9 insect cells
were infected with recombinant baculovirus encoding rat type II adeny-
lyl cyclase (47) and harvested 48 h after infection. Sf9 membranes
containing type II adenylyl cyclase (5 mg of protein/assay tube) were
reconstituted with GTPgS-activated Gs a subunit (48) and varying
concentrations of bg dimers on ice for 30 min. The reaction was initiated
by addition of the reconstituted membranes to the reaction buffer
containing 25 mM HEPES, pH 8.0, 10 mM phosphocreatine, 10 units/ml
of creatine phosphokinase, 0.4 mM 3-isobutyl-1-methylxanthine, 10 mM
MgCl2, 0.5 mM ATP, and 0.1 mg/ml BSA and incubated for 7 min at
30 °C. The assay was stopped by addition of 0.1 N HCl and cyclic AMP
measured using an automated radioimmunoassay (49).
Electrophoresis—For quantitation of the bg concentration in vesicles,
the bg dimers reconstituted into phospholipid vesicles were electro-
phoresed on a 12% acrylamide, sodium dodecyl sulfate-polyacrylamide
gel and stained with silver according to the method of Bloom et al. (50).
The bg concentrations in the gel were estimated using the amount of
stained b subunit protein as compared with ovalbumin standards run
in the same gel. The stained proteins were quantitated using a Bio-
Image scanning densitometer and the Whole Band® software (Bio-
Image, Ann Arbor, MI) as described (36, 40). The accuracy of this
procedure was verified by comparison with the BCA (Pierce) protein
assay (40). To better display the mobility of the g subunits, Tricine/
SDS-polyacrylamide gels were run according to the procedure of Schag-
ger and von Jagow (51). The separating gel contained 16.5% total
acrylamide, 0.4% bisacrylamide, and 10% (v/v) glycerol. The stacking
gel contained 4% total acrylamide and 0.1% bisacrylamide. Gels were
run at constant voltage (;100 volts) at 10 °C for 4–5 h. Resolved
proteins were stained with silver according to the method of Morrissey
(52) with the modification that the dithiothreitol incubation was re-
duced to 15 min.
Calculation and Expression of Results—Experiments presented un-
der “Results” are representative of three or more similar experiments.
Data expressed as concentration-response curves were fit to sigmoid
curves using the fitting routines in the GraphPad Prism™ software.
Statistical differences between the curves were determined using all
the individual data points from multiple experiments to calculate the F
statistic as described (53).
Materials—All reagents used in the culture of Sf9 cells and for the
expression and purification of G protein bg subunits have been de-
scribed previously in detail (34, 35). The baculovirus transfer vector,
pVL1393, was purchased from Invitrogen; the BaculoGold® kit from
PharMingen; 10% Genapol C-100 and phosphatidylinositol 4,5-bisphos-
phate from Calbiochem®; phosphatidylethanolamine (bovine heart)
from Avanti Polar Lipids, Inc.; [inositol-2-3H]phosphatidylinositol 4,5-
bisphosphate from NEN Life Science Products; CHAPS from Roche
Molecular Biochemicals; BSA (fatty acid-free) from Sigma; the pCNTR
shuttle vector from 5 Prime3 3 Prime, Inc. (Boulder, CO); Q-Sepharose
FF, heparin-Sepharose CL-6B, Sephacryl S-300, and FPLC Mono Q HR
5/5 columns from Amersham Pharmacia Biotech; and HPHT hydroxy-
lapatite from Bio-Rad. All other reagents were of the highest purity
available.
RESULTS
To determine the role of the prenyl modification of the g
subunit in the interaction of bg dimers with effectors, the
CAAX motifs in the g1, g2, and g11 subunits were altered to
direct the addition of different prenyl isoprenoids. Each g sub-
unit was co-expressed with the b1 subunit in Sf9 insect cells,
and the six bg dimers, b1g1, b1g1-S74L, b1g2, b1g2-L71S, b1g11,
and b1g11-S73L, were purified using ai1-agarose affinity chroma-
tography and tested for their ability to activate two effectors,
PLC-b and type II adenylyl cyclase. All six g subunits were
analyzed by mass spectrometry to ensure that their CAAX
motifs were appropriately processed. The results of the analy-
sis showed that each g subunit had the expected isoprenoid
lipids at its C terminus with the extent of processing ranging
from 70 to 95% (see “Experimental Procedures”). Therefore, all
bg dimers used in this study are capable of high-affinity inter-
actions with a subunits, receptors, and effectors. The purity of
these dimers is shown in Fig. 1A. The purity of the three
recombinant PLC-b isoforms used in this study is shown in Fig.
1B.
Differential Effect of Three Different bg Dimers on PLC-b and
Adenylyl Cyclase Activity—We compared the ability of bg
dimers with g subunits containing either a farnesyl or a gera-
nylgeranyl moiety to stimulate PLC-b. An assay system was
used in which purified bg dimers were reconstituted into ex-
truded phospholipid vesicles and the vesicles separated from
mono-dispersed bg dimers and the detergent used to solubilize
G proteins on an Ultrogel AcA34 column (40). The data in Fig.
2A illustrate the ability of three bg dimers to activate recom-
binant turkey PLC-b. Avian PLC-b was used initially, because
it has a lower basal activity and higher bg subunit-stimulated
activity than either the mammalian PLC-b1 or PLC-b2
isozymes (39) (see also Fig. 3). The b1g2 dimer activated turkey
PLC-b about 10-fold with an estimated EC50 value of 0.7 nM
(refer to Table II). The b1g11 and b1g1 subunits activated tur-
key PLC-b with estimated EC50 values of 4.1 and 1.9 nM,
respectively. The Vmax values were 50–60% of those observed
with the b1g2 dimer (refer to Table II). Therefore, the b1g2
dimer is more potent and effective in activating PLC-b than
either b1g1 or b1g11, and the potency of b1g11 is less than that
of b1g1. The data in Fig. 2B compare the ability of the three bg
dimers to activate type II adenylyl cyclase. The b1g2 dimer
activated type II adenylyl cyclase about 12-fold with an esti-
mated EC50 value of 14 nM. However, neither b1g1 (54) nor
b1g11 effectively activated type II adenylyl cyclase. Since the g
subunits were combined with the same b1 subunit, these re-
sults indicate that differences in the activation of either PLC-b
or type II adenylyl cyclase are due to differences in the g
subunit. The major differences between the known g subunits
are their divergent amino acid sequences and their lipid mod-
ifications. Interestingly, the data in Fig. 2A show that bg
dimers containing the g2 subunit modified with a geranylgera-
nyl group are more potent and effective in activating both
effectors than those containing either the g1 or the g11 subunit
modified with a farnesyl group. Therefore, to address the pos-
sibility that the identity of the prenyl group on the g subunit is
an important determinant of the dimer’s activity, the CAAX
motif in the g2 subunit was altered to direct the addition of the
farnesyl group and the ability of the b1g2-L71S dimer to activate
three PLC-b isoforms was examined.
FIG. 1. Sodium dodecyl sulfate-polyacrylamide electrophore-
sis of purified G protein bg subunits and three PLC-b isoforms.
A, purified, recombinant bg subunits of defined subtypes were electro-
phoresed on a 16% acrylamide, 10% (v/v) glycerol, sodium dodecyl
sulfate-Tricine gel and stained with silver. The migration of the b and
g subunits are indicated on the left. B, three isoforms of purified,
recombinant PLC-b were electrophoresed on a 8% acrylamide SDS-
PAGE and stained with silver. The mobility of the molecular weight
standards is indicated on the left.
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Effect of b1g2 and b1g2-L71S on PLC-b Activity—The data in
Fig. 3 show that the b1g2 dimer stimulated PLC-b with a
subnanomolar potency and that exchanging the prenyl group
on the g2 subunit from geranylgeranyl to farnesyl (b1g2-L71S)
caused a diminution in the ability of the b1g2 dimer to activate
all three isoforms of PLC-b. The farnesyl-modified b1g2-L71S
dimer was less potent and effective in activating turkey PLC-b
than the native b1g2 dimer (Fig. 3A). Fitting the data to sig-
moid curves estimated that the maximal stimulation with the
b1g2-L71S dimer decreased by 35% and that the EC50 value
increased from 0.7 to 1.2 nM (refer to Table II). Similarly, the
b1g2-L71S dimer was less potent and effective than the native
b1g2 dimer in the activation of human PLC-b2 (Fig. 3B). The
data in Fig. 3C indicate that the bg subunits produced little
effect on the activity of PLC-b1 as demonstrated previously (5,
44, 45, 55, 56). Thus, bg subunits stimulated activity in the
order of tPLC-b $ PLC-b2 ... PLC-b1. Overall, these results
indicate that the prenyl group on the g subunit is an important
determinant of the interaction between PLC-b and bg dimers.
Partition of Different Recombinant bg Dimers into Phospho-
lipid Vesicles—Since most studies of G protein activation of
PLC-b have used the reconstitution of pre-aggregated lipid
with a or bg subunits to activate PLC-b, a potential problem
might arise if bg dimers containing different isoprenoid lipids
did not partition equally into pre-aggregated lipid layers. This
is especially important considering the different chain lengths
of the lipids associated with the native g1, g2, or g11 subunits.
To determine the partitioning into vesicles of the six different
bg dimers used in this study, fractions 2 and 3 from the AcA34
column were collected and the amount of protein inserted into
the vesicles was measured as described (40). Table I shows that
both native b1g1 and b1g11 dimers containing farnesyl groups
partitioned equally with the native b1g2 dimer containing a
geranylgeranyl group. About 27% of the bg dimers added to the
FIG. 2. Differential abilities of three bg dimers to regulate
PLC-b and adenylyl cyclase. A, the ability of the b1g1 and b1g11
dimers to activate phospholipase C-b as compared with that of the b1g2
dimer. Extruded phospholipid vesicles containing phosphatidylinositol
4,5-bisphosphate were reconstituted with 0.01, 0.03, 0.1, 0.3, 1.0, 3.0, or
10.0 mg of each bg dimer on ice for 30 min. The mixture was applied to
a 2-ml Ultrogel AcA34 column, fraction 2 was collected, and the ability
of b1g1 (open circles), b1g2 (closed squares), and b1g11 (closed triangles)
in fraction 2 to stimulate turkey PLC-b activity was measured as
described under “Experimental Procedures.” The difference between
the effect of b1g2 and either b1g1 or b1g11 was statistically significant
(p , 0.0001). B, comparison of the ability of three bg dimers to stimu-
late type II adenylyl cyclase. Sf9 cells were infected with a recombinant
baculovirus encoding type II adenylyl cyclase, membranes prepared,
and the cyclase reaction performed with the indicated concentrations of
three recombinant bg dimers as described under “Experimental Proce-
dures.” The results are representative of six similar experiments, each
performed in duplicate. Sigmoid curves were fit to the data and statis-
tical differences between the curves determined as described under
“Experimental Procedures.” The difference between the effect of b1g2
and either b1g1 or b1g11 was statistically significant (p , 0.0001).
FIG. 3. Comparison of the activity of the b1g2 and b1g2-L71S
dimers to activate three different isoforms of purified PLC-b. A,
the ability of b1g2 (modified with geranylgeranyl; closed squares) and
b1g2-L71S (modified with farnesyl; open squares) to stimulate recombi-
nant turkey PLC-b (tPLC-b) was measured as described under “Exper-
imental Procedures.” The difference between the effect of b1g2 and
b1g2-L71S was statistically significant (p , 0.001). B, analogous experi-
ments were performed with recombinant human PLC-b2 (hPLC-b2).
The difference between the effect of b1g2 and b1g2-L71S was statistically
significant (p , 0.001). C, analogous experiments were performed with
human PLC-b1 (hPLC-b1).
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reaction mixture were incorporated into the phospholipid ves-
icles isolated in fractions 2 and 3. Moreover, the bg dimers with
altered CAAX sequences partitioned equally with native bg
dimers. Therefore, the length of the prenyl chain does not
significantly affect the concentration of bg dimers reconsti-
tuted into phospholipid vesicles containing phosphatidylinosi-
tol 4,5-bisphosphate.
Effect of b1g1, b1g1-S74L, b1g11, and b1g11-S73L on PLC-b
Activity—It was important to determine whether switching the
farnesyl group to geranylgeranyl improves the ability of either
the b1g1 or the b1g11 dimer to activate PLC-b. Thus, the CAAX
motifs in the g1 and g11 subunits were altered to direct the
addition of a geranylgeranyl group, and the ability of both the
b1g1-S74L and b1g11-S73L dimers to activate either turkey PLC-b
or human PLC-b2 was examined. The data in Fig. 4A show that
the geranylgeranyl-modified b1g1-S74L dimer exhibited an in-
creased potency and maximal activity compared with the na-
tive b1g1 dimer. Similarly, the geranylgeranyl-modified b1g11-
S73L dimer was more potent and effective in activating turkey
PLC-b than the native b1g11 dimer. The b1g1-S74L and b1g11-
S73L dimers also exhibited increased capacity to stimulate hu-
man PLC-b2 activity (Fig. 5). These four bg dimers (b1g1,
b1g1-S74L, b1g11, and b1g11-S73L) showed little effect on the
activity of PLC-b1 (data not shown, but see Fig. 3C). The data
in Table II summarize the potency and efficacy of the six bg
dimers used in this study on the activation of these two PLC-b
isoforms. The b1g1-S74L dimer exhibited an about 1.6-fold in-
crease in maximal activity as compared with the native b1g1
dimer and the EC50 value decreased from 1.9 to 1.1 nM. The
estimated maximal activity of the b1g11-S73L dimer increased
about 1.3-fold and the EC50 value decreased from 4.1 to 1.6 nM.
Similar changes were observed in the ability of the dimers to
activate human PLC-b2. Taken together, the data indicate that
bg dimers with a g subunit containing a geranylgeranyl group
interact with higher affinity with PLC-b than bg dimers with a
g subunit containing a farnesyl group.
Effect of the Prenyl Group on the Activity of Type II Adenylyl
Cyclase—To determine the role of the isoprenoid group in the
interaction with an effector which is membrane-associated, the
capacity of the six bg dimers to activate type II adenylyl cyclase
was also examined. The data in Fig. 6A indicate that switching
the prenyl group on the g2 subunit from geranylgeranyl to
farnesyl caused a significant decrement in the ability of the
b1g2 dimer to activate type II adenylyl cyclase. Our previous
experiments showed that about the same amount of the b1g2
and b1g2-L71S (about 25% of the bg subunits added to a recon-
stitution mixture) are incorporated into Sf9 cell membrane,
indicating regardless of the prenyl group on the g subunit, the
dimers partition equally into the Sf9 cell membrane (30). Thus,
the result from Fig. 6A suggests that the type of prenyl group
is important for the interaction of the bg dimer with adenylyl
cyclase. As expected, the b1g1 dimer did not activate type II
adenylyl cyclase (54). Interestingly, the b1g11 dimer was com-
pletely ineffective on type II adenylyl cyclase. Surprisingly,
neither the b1g1-S74L nor the b1g11-S73L dimer containing a
geranylgeranyl group on the g subunit were able to signifi-
cantly stimulate type II adenylyl cyclase (Fig. 6, B and C). The
data in Table III summarize the potency and efficacy of the six
bg dimers on the activation of type II adenylyl cyclase. The
farnesyl-modified b1g2-L71S dimer was about 60–65% less ac-
tive, and its EC50 value was increased from 14 to 76 nM. This
change in potency and maximal activity is larger than that
observed with PLC-b (see Fig. 3). Thus, bg dimers with a g
subunit containing a geranylgeranyl group interact with
higher affinity with type II adenylyl cyclase than those with a
FIG. 4. Comparison of the activity of native and altered bg
dimers to stimulate recombinant turkey PLC-b. A, the ability of
b1g1 (modified with farnesyl; open circles) and b1g1-S74L (modified with
geranylgeranyl; closed circles) dimers to stimulate recombinant turkey
PLC-b (tPLC-b) was measured as described under “Experimental Pro-
cedures.” The difference between the effect of b1g1 and b1g1-S74L was
statistically significant (p , 0.001). B, analogous experiments were
performed with b1g11 (modified with farnesyl; closed triangles) and
b1g11-S73L (modified with geranylgeranyl; open triangles) dimers. The
difference between the effect of b1g11 and b1g11-S73L was statistically
significant (p , 0.001).
TABLE I
Partition of different recombinant bg dimers into phospholipid vesicles
Purified bg subunits were mixed with phospholipid vesicles, reconstituted on ice for 30 min, applied to a 2-ml Ultrogel AcA34 column at 4 °C,
and fractions 2 and 3 eluting at the void volume of the column used for measurement of the amount of dimer inserted into the vesicles. The amount
of phospholipid eluted and bg dimers bound to the vesicles were quantitated as described under “Experimental Procedures.” Data are represent-
ative of three separate experiments.
bg dimer Added dimer
Dimer incorporated into vesicles Total reconstituted,
fractions 2 1 3Fraction 2 Fraction 3
ng ng %
b1g1 3010 289 (9.6%) 551 (18.3%) 27.9
b1g1-S74L 3009 280 (9.3%) 595 (19.8%) 29.1
b1g2 3026 306 (10.1%) 503 (16.6%) 26.7
b1g2-L71S 2990 286 (9.6%) 501 (16.8%) 26.4
b1g11 2970 302 (10.2%) 560 (18.9%) 29.1
b1g11-S73L 3006 278 (9.2%) 523 (17.4%) 26.6
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g subunit containing a farnesyl group. While these results are
not surprising, the observation that neither the g1 or the g11
subunit modified with a geranylgeranyl group have any activ-
ity on type II cyclase was unexpected. These observations sug-
gest that the differences in amino acid sequence between g1
and g2 greatly affect the ability of the dimers to activate ad-
enylyl cyclase.
DISCUSSION
This study demonstrates that bg dimers with g subunits
containing different isoprenoids have distinct abilities to acti-
vate PLC-b and type II adenylyl cyclase. The two major find-
ings of this study are (a) the isoprenoid lipid added to the
FIG. 5. Comparison of the activity of native and altered bg
dimers to stimulate recombinant human PLC-b2. A, phospholipid
vesicles reconstituted with b1g1 (modified with farnesyl; open circles) or
b1g1-S74L (modified with geranylgeranyl; closed circles) dimer were in-
cubated with recombinant human PLC-b2 (hPLC-b2) and PLC-b activ-
ity measured as described under “Experimental Procedures.” The data
were fit to sigmoid curves. The difference between the effect of b1g1 and
b1g1-S74L was statistically significant (p , 0.001). B, analogous experi-
ments were performed with b1g11 (modified with farnesyl; closed trian-
gles) and b1g11-S73L (modified with geranylgeranyl; open triangles)
dimers. The difference between the effect of b1g11 and b1g11-S73L was
statistically significant (p , 0.001).
TABLE II
Comparison of EC50 and Vmax of six bg dimers on the activation of
two PLC-b isoforms
Phospholipid vesicles containing phosphatidylinositol 4,5-bisphos-
phate were reconstituted with different recombinant bg dimers on ice
for 30 min. After the incubation, the mixture was applied to a 2-ml
Ultrogel AcA34 column at 4 °C and fraction 2 eluting at the void volume
used for the measurement of PLC-b activity. Fraction 2 was incubated
for 15 min at 30 °C in the presence of purified recombinant turkey
PLC-b (tPLC-b) or human PLC-b2 (hPLC-b2) as described under “Ex-
perimental Procedures.” The data are expressed as mean 6 S.E. and the
average of three determinations, each performed in duplicate. The EC50
(nM) and Vmax (mmol/mg of PLC/min) values were estimated by fitting of
the averaged data to sigmoid curves.
bg dimer
tPLC-b hPLC-b2





b1g1 1.9 6 0.2 1.63 6 0.08 2.7 6 0.1 1.37 6 0.06
b1g1-S74L 1.1 6 0.3 2.60 6 0.04 1.7 6 0.2 2.37 6 0.07
b1g2 0.7 6 0.2 3.15 6 0.05 1.0 6 0.2 2.52 6 0.03
b1g2-L71S 1.2 6 0.2 2.04 6 0.11 1.6 6 0.1 1.85 6 0.11
b1g11 4.1 6 0.6 1.86 6 0.10 4.0 6 0.3 1.45 6 0.17
b1g11-S73L 1.6 6 0.1 2.42 6 0.08 2.2 6 0.5 2.52 6 0.13
FIG. 6. Comparison of the activity of native and altered bg
dimers to stimulate type II adenylyl cyclase. A, Sf9 cells were
infected with a recombinant baculovirus encoding the type II adenylyl
cyclase, membranes prepared, and the cyclase reaction performed with
the indicated concentrations of b1g2 (modified with geranylgeranyl;
closed squares) and b1g2-L71S (modified with farnesyl; open squares) as
described under “Experimental Procedures.” The difference between
the effect of b1g2 and b1g2-L71S was statistically significant (p , 0.0001).
B, the cyclase reaction was performed with the indicated concentrations
of b1g1 (modified with farnesyl; open circles) and b1g1-S74L (modified
with geranylgeranyl; closed circles) and compared with the effect of b1g2
(dotted lines). The difference between the effect of b1g2 and b1g1 was
statistically significant (p , 0.0001), but the difference between b1g1
and b1g1-S74L was not statistically significant. C, analogous experiments
were performed with b1g11 (modified with farnesyl; closed triangles)
and b1g11-S73L (modified with geranylgeranyl; open triangles) dimers.
The difference between the effect of b1g2 and b1g11 was statistically
significant (p , 0.0001), but the difference between b1g11 and b1g11-S73L
was not significant.
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cysteine residue in the CAAX motif of the g subunit plays a role
in determining the activity of the bg dimer at both effectors and
(b) bg dimers with a g subunit containing a geranylgeranyl
group are more potent and effective in activating either PLC-b
or type II adenylyl cyclase than those with a g subunit contain-
ing a farnesyl group. This study also presents the first demon-
stration of the functional activity of a bg dimer containing the
g11 subunit. The b1g11 dimer is about six times less potent and
about 50% less effective in activating PLC-b than the b1g2
dimer and has little or no effect on the type II adenylyl cyclase.
Overall, the data presented here indicate that in addition to the
primary amino acid sequence of the g subunits, the prenyl
group on the g subunit is an important determinant of the
activation of PLC-b and type II adenylyl cyclase.
The recent x-ray crystal structure of a complex of bovine
retinal phosducin with the transducin bg subunit in which the
g subunit contained a farnesyl group provides a conceptual
background for interpreting the results obtained with PLC-b
and adenylyl cyclase (31). Remarkably, the interaction between
phosducin and the bg dimer appears to result in a significant
conformational change in the b subunit as compared with the
conformation seen in the free bg dimer (32). This event also
appears to cause the insertion of the prenyl group into a hy-
drophobic pocket in the b subunit formed between blades 6 and
7 (31). Interestingly, this conformational change occurs on the
outer strands of blades 6 and 7 of the b propeller and recent
mutagenesis studies show that these regions are critical for the
activation of PLC-b (57). If the hydrophobic pocket within the b
subunit that binds the prenyl group is able to discriminate
between the different length of the farnesyl and geranylgeranyl
lipids, different conformational changes might be induced by
the g1 and g2 subunits (or their prenyl mutants). This possibil-
ity might explain differences in the ability of the various bg
dimers to stimulate the activity of PLC-b and adenylyl cyclase.
Overall, these observations suggest that insertion of a prenyl
group into the hydrophobic pocket formed in the b subunit may
be an important part of the mechanism by which the bg dimers
activate effectors when released from the a subunit.
The interaction of protein prenyltransferases with their iso-
prenoid substrates provides another example of a hydrophobic
binding pocket determining isoprenoid specificity. Protein pre-
nyltransferases are responsible for the addition of isoprenoid
lipid to proteins and are classified by their lipid substrate:
protein farnesyltransferase (FTase), protein geranylgeranyl-
transferase (GGTase-I), and the Rab geranylgeranyltrans-
ferase (GGTase-II) (58). G protein g subunits are targets for
either FTase or GGTase-I. These two prenyltransferases are
heterodimers composed of the common 48-kDa a subunit and
distinct b subunits: 46-kDa b subunit for FTase (bF) and 43-
kDa b subunit for GGTase-I (bGGI) (59–62). Thus, the binding
sites for different lipid substrates on these two prenyltrans-
ferases are thought to reside in their b subunits (58). The x-ray
crystal structure determined by Park et al. (63) illustrates that
farnesyl diphosphate occupies a hydrophobic pocket in the cen-
ter of the b subunit barrel. Recently, it has been demonstrated
that the isoprenoid moiety of farnesyl diphosphate binds in an
extended conformation within the hydrophobic cavity of the b
subunit of the FTase, and the diphosphate moiety binds to a
positively charged cleft at the top of this cavity near the sub-
unit interface (64). These findings suggest that the isoprenoid
substrate specificity of the hydrophobic binding cavity is deter-
mined by the depth of the cavity and that the pocket acts as a
ruler discriminating between isoprenoids of different length
(64).
The three classes of PLC isozymes, PLC-b, PLC-g, and
PLC-d, contain two highly conserved catalytic domains, X and
Y, but only the PLC-b isoforms are regulated by G proteins
(65). These isoforms are distinguished from the other families
by an extended C terminus. Deletion of the C-terminal amino
acids of PLC-b1 and PLC-b2 eliminated Gq a subunit-mediated
PLC-b activation (66–68). Peptides corresponding to a portion
of the C-terminal region of PLC-b1 inhibited activation by Gq a
subunit in vitro (67), suggesting that the C-terminal region
might be important for the a subunit-induced PLC-b activa-
tion. Since removal of the C-terminal region of PLC-b1 and
PLC-b2 did not impair bg subunit-induced enzyme activation,
the remaining domains of the enzyme must provide the bg
subunit interaction sites. A PLC-b2 fragment corresponding to
a region between the X and Y domains (Glu435 to Val641) inhib-
ited bg subunit-mediated activation of PLC-b2 in transfected
COS-7 cells (69). Peptides from this sequence expressed as a
series of fusion proteins bound to purified bg subunits in vitro
(69). Overexpression of this region also blocked bg subunit-
induced activation of co-transfected PLC-b2 in COS cells (69).
It has been reported recently that two overlapping PLC-b2
fragments corresponding to Asn564–Lys583 and Glu574–Lys593
of PLC-b2 inhibited activation of PLC-b2 by bg subunits, in-
hibited bg subunit-dependent ADP-ribosylation of Gi1 a sub-
unit by pertussis toxin, and inhibited bg subunit-dependent
activation of phosphoinositide 3-kinase (70). These observa-
tions suggest that the region between Glu574 and Lys583 in
PLC-b2 may be the site that interacts with bg subunits (70).
A number of studies have attempted to determine the sites at
which the bg dimer interacts with adenylyl cyclase. Type I
adenylyl cyclase is inhibited by Gi a subunits and bg subunits,
whereas type II cyclase is activated by the bg subunits in the
presence of Gs a subunits (7, 71). In an attempt to identify the
sites in adenylyl cyclase that interact with the bg subunits, a
chimeric soluble adenylyl cyclase was engineered by linking
the type I adenylyl cyclase C1a domain (the N-terminal part of
the first cytoplasmic domain) with the type II adenylyl cyclase
C2 domain (the second cytoplasmic domain) (72, 73). The chi-
meric soluble enzyme was unresponsive to the Gi a subunit but
was inhibited almost completely by the b1g2 dimer, suggesting
that the C1a domain is critical for bg subunit-induced inhibi-
tion of type I adenylyl cyclase (72, 73). In contrast, a 27-amino
acid peptide (956–982) derived from the C2 domain of type II
adenylyl cyclase blocked the interaction of bg dimers with
several effectors, including PLC-b, type II adenylyl cyclase, and
K1 channels, but did not block bg interaction with a subunits
(74). This result suggests that bg dimers can also interact with
a region on the C2 domain of type II adenylyl cyclase (74).
Whereas the G protein b1–b4 subunits are highly conserved
TABLE III
Comparison of EC50 and Vmax of six bg dimers on the activation of
type II adenylyl cyclase
Sf9 cells were infected with a recombinant baculovirus encoding the
type II adenylyl cyclase, membranes prepared, and the cyclase reaction
performed with the range of bg dimer concentrations described under
“Experimental Procedures.” The data are expressed as mean 6 S.E. and
the average of three determinations, each performed in duplicate. The
EC50 (nM) and Vmax (nmol/mg of protein/min) values were estimated by
fitting of the averaged data to sigmoid curves.
bg dimer




b1g1 97.4 6 7.2 1.67 6 0.03
b1g1-S74L 85.1 6 10.6 3.04 6 0.63
b1g2 13.9 6 1.1 18.34 6 1.65
b1g2-L71S 76.3 6 10.5 7.17 6 1.82
b1g11 79.8 6 8.9 2.85 6 0.89
b1g11-S73L 66.9 6 6.2 4.67 6 0.89
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in primary amino acid sequence, the g subunits are much more
divergent, suggesting that the functional specificity of different
bg dimer combinations may be due to the differences in g
subunits. The results presented here support this possibility.
Combination of different g subunits with the same b subunit
resulted in bg dimers exhibiting very different ability to acti-
vate PLC-b and adenylyl cyclase. The differences are due both
to the primary amino acid sequences of the g subunits and to
their lipid modifications. For example, all bg dimers containing
a geranylgeranyl group on the g subunit were more potent and
effective in activating the two effectors than those containing a
farnesyl group. Thus, the type of lipid at the C terminus of the
g subunit is important to the ability of bg dimers to activate
effectors. Other groups have also obtained data suggesting that
the isoprenoid lipid is important in the interaction of bg dimers
with effectors. Matsuda et al. (29) have shown that the b1g1-
S74L dimer containing a mixture of farnesyl and geranylgeranyl
groups had a greater ability to inhibit Ca21/calmodulin-stimu-
lated adenylyl cyclase and stimulate PLC-b than did the native
farnesylated b1g1 dimer. However, our data suggest that the
amino acid sequence of the g subunit is also an important
determinant of the activity of the bg dimer. For example, nei-
ther the b1g1 nor the b1g11 dimer are able to activate type II
adenylyl cyclase. In contrast to the results obtained with
PLC-b, switching the prenyl group in the b1g1 and b1g11 dimers
to geranylgeranyl did not increase their ability to activate type
II adenylyl cyclase. Overall, these results indicate that both the
primary amino acid sequence and the prenyl group of the g
subunits are important determinants for the activation of ef-
fectors. For the activation of PLC-b, the type of prenyl group
appears to be a major determinant of the activity of bg dimer.
In the case of type II adenylyl cyclase, the prenyl group also
appears to be important, but the amino acid sequences of cer-
tain g subunits, such as g1 and g11, appear to be incapable of
activating the enzyme regardless of prenyl group at their C
terminus.
Our previous data supports the possibility that charge dif-
ferences in the g subunit can have a large effect on the ability
of bg dimers to activate type II adenylyl cyclase. Phosphoryla-
tion of the g12 subunit in the b1g12 dimer significantly inhibits
the ability of the dimer to stimulate type II adenylyl cyclase
(46), and the phosphorylation site has been determined to be at
Ser1 in the N terminus of the molecule (11). This result sug-
gests that introduction of negative charges at the N-terminal
region of the g subunit inhibits the interaction of the bg dimer
with the type II adenylyl cyclase. Interestingly, comparison of
the N-terminal 20 amino acids of the g2 with the g1 or g11
subunits shows that g1 and g11 have six negatively charged
amino acids whereas g2 has only one. Thus, the negatively
charged N terminus of the g1 and g11 subunits may explain the
inability of dimers containing these g subunits to activate type
II adenylyl cyclase. Preliminary experiments with chimeric g
subunits in which the N-terminal 20 amino acids of g2 were
replaced with the corresponding amino acids from g1 support
this explanation. When expressed with the b1 subunit, this
dimer has a greatly reduced ability to stimulate type II adeny-
lyl cyclase.2 Thus, multiple domains of the g subunit may be
involved in the interaction with different effectors.
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